MEDICO2024-10-012024-12-31 MEDICO2024-10-012024-12-31 MEDICO2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member MEDICO2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member MEDICO2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 540937 MEDICO NOTLISTED Medico Remedies Limited Equity 2024-04-01 2025-03-31 2025-02-05 2025-01-30 INR Lakhs Third quarter 15:00:00 15:30:00 2025-02-05 2025-02-05 Not applicable Single segment manufacturer and exporter of pharmaceutical formulations 2024-10-01 2024-12-31 Unaudited Standalone 394899000.00 14250000.00 409149000.00 309290000.00 3339000.00 -26014000.00 18758000.00 2762000.00 7641000.00 58395000.00 374171000.00 34978000.00 0.00 34978000.00 7914000.00 868000.00 8782000.00 0.00 26196000.00 0.00 0.00 0.00 0.00 26196000.00 23000.00 26219000.00 0.00 0.00 165968000.00 2 0.32 0.32 0.00 0.00 0.32 0.32 0.00 0.00 0.00 1.The above unaudited standalone financial results of the company were reviewed and recommended by the audit committee on February 05, 2025 and subsequently approved by the Board of Directors at its meeting held on February 05, 2025. The review report has been filed with stock exchange and is available on the Company’s website. 2.The figures for the quarter ended on 31st December, 2024 are balancing figures between the reviewed figures for the quarter ended 30th September 2024 and reviewed year to date figures upto nine month ended 31st December, 2024. 3.The standalone financial results for the quarter ended on 31st December, 2024 have been subjected to Limited Review by statutory auditors of the company and the statutory auditors have issued unmodified report on unaudited financial results. 4.The above financial results have been prepared as per IND AS and all standards and requirements of IND AS are complied with by the company. 5.Medico Remedies Limited is a pharmaceutical formulation manufacturing company and the management reviews the performance of the company as a single operating segment in accordance with IND-AS 108 “Operating Segments” notified pursuant to Companies (Accounting Standard) Rules, 2015. Accordingly, no segment information/segment reporting has been furnished within. Details of geographical segments are disclosed below: PARTICULARS QE 31.12.2024 QE 30.09.2024 Amount (Rs. In Lakh) Amount (Rs. In Lakh) 1) Sales of products within India 71.47 244.40 2) Sales of products Outside India 3842.90 3655.85 Total 3914.37 3900.25 6.Previous periods figures have been regrouped / reclassified where required to make them compatible with the figures of current periods. 7.The company does not have any subsidiary/associate/joint venture company as on December 31, 2024 8.The results for the quarter ended December 31,2024 is available on the BSE Limited website (URL: www.bseindia.com), NSE Limited website (URL: www.nseindia.com) and on the Company’s website (URL: www.medicoremedies.com) Single segment 2024-04-01 2024-12-31 Unaudited Standalone 1096374000.00 23964000.00 1120338000.00 819738000.00 15383000.00 -25469000.00 46950000.00 6645000.00 22645000.00 156394000.00 1042286000.00 78052000.00 0.00 78052000.00 19254000.00 1274000.00 20528000.00 0.00 57524000.00 0.00 0.00 0.00 0.00 57524000.00 67000.00 57591000.00 0.00 0.00 165968000.00 2 0.69 0.69 0.00 0.00 0.69 0.69 0.00 0.00 0.00 Other Expenses 58395000.00 Other Expenses 156394000.00 -23000.00 -67000.00 0.00 0.00